Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses

Ciba Found Symp. 1994;187:229-40; discussion 240-4. doi: 10.1002/9780470514672.ch15.


Many tumours express tumour-specific antigens capable of being presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules. Current models of antigen presentation predict that the tumour cell itself should present its own MHC class I-restricted antigens to T cells. Earlier cross-priming experiments have demonstrated that at least some MHC class I-restricted antigens may also be presented by bystander cells. There is no detectable presentation of MHC class I-restricted tumour antigens by the tumour itself during priming of tumour-specific responses. The tumour antigens are presented exclusively by host bone marrow-derived cells. These results imply that an efficient mechanism exists in vivo for transfer of MHC I-restricted antigens to bone marrow-derived antigen presenting cells. They also suggest that HLA matching may not be critical in the clinical application of allogeneic tumour vaccines.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Neoplasm / biosynthesis*
  • Antigen Presentation*
  • Antigens, Neoplasm / immunology*
  • Bone Marrow Cells*
  • Histocompatibility Antigens Class I / immunology*
  • Humans
  • Mice


  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • Histocompatibility Antigens Class I